← FDA DRUG APPROVALS

FDA NDA · NDA018557

FANSIDAR

Sponsor: ROCHE

APPLICATION
NDA018557
TYPE
NDA
ORIGINAL APPROVAL
1981-10-28
LATEST ACTION
2004-02-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

FANSIDARDiscontinued
PYRIMETHAMINE 25MG, SULFADOXINE 500MG · TABLET · ORAL

Approval history

2004-02-26Labeling · Supplement 15 · priorityReviewAP
2003-04-27Labeling · Supplement 16 · priorityLetterAP
1998-08-14Manufacturing (CMC) · Supplement 14 · priorityAP
1993-06-09Manufacturing (CMC) · Supplement 13 · priorityAP
1987-11-03Labeling · Supplement 12 · priorityAP
1987-04-30Labeling · Supplement 11 · priorityAP
1985-07-24Labeling · Supplement 7 · priorityAP
1985-07-24Labeling · Supplement 10 · priorityAP
1985-07-24Labeling · Supplement 8 · priorityAP
1985-07-24Labeling · Supplement 9 · priorityAP
1983-10-26Manufacturing (CMC) · Supplement 6 · priorityAP
1983-07-26Manufacturing (CMC) · Supplement 5 · priorityAP
1983-07-21Manufacturing (CMC) · Supplement 3 · priorityAP
1983-07-21Manufacturing (CMC) · Supplement 2 · priorityAP
1981-10-28Type 1 - New Molecular Entity and Type 4 - New Combination · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →